Cardiovascular
CV · guidelines, resources & primary literature
Guidelines & Resources
General
- Cardiovascular Risk Assessment and Targets — RxFiles
- CCS Pocket Guides — CCS
- Cardiac POCUS — POCUS 101
- QT Prolongation Med List — CredibleMeds
CAD
- Major Dyslipidemia Trials — RxFiles
- Anti-platelet Guidelines — CCS 2023
- Acute STEMI Management — CCS 2019
- Stable CAD Management — ESC 2024
- Anti-platelet Pocket Guide — CCS 2018
- CKD and CAD — JACC Review 2019
- Post-MI Meds and Evidence — RxFiles
- Angina Management — RxFiles
- Dual Pathway and Triple Therapy — RxFiles
- ICD Guideline (Primary and Secondary Prevention) — CCS 2016
Atrial Fibrillation
- Catheter/Surgical Ablation Guidelines — Heart Rhythm Societies 2024
- AFib Pocket Guide — CCS 2021
- DOAC in Patients requiring Anti-Platelet Therapy — Thrombosis Canada 2025
- Dual Pathway and Triple Therapy — RxFiles
CHF
- Left Heart Failure Pathogenesis — Calgary Guide
- HFrEF Pocket Guide — CCS 2021
- HFnrEF Guideline — CCS 2025
- CRT Pocket Guide — CCS 2013
Hypertension
- HTN Guidelines — CHEP 2025
- HTN Guideline Summary — RxFiles
- HTN Trial Summaries up to 2020 — RxFiles
Pulmonary Hypertension
- Definition, classification and diagnosis of pHTN — WSPH 2024
- pHTN Guidelines — ESC 2022
Primary Literature
Physical Exam
- Does This Patient With Chest Pain Have Acute Coronary Syndrome? — JAMA 2015
- Did this patient have Cardiac Syncope? — JAMA 2019
- Does This Patient Have Volume Overload? — JAMA 2026
Incretin Therapy & Cardiometabolic Outcomes
- SELECT — Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — NEJM 2023
- SURPASS-EARLY — Tirzepatide Versus Intensified Conventional Care in Early Type 2 Diabetes — Annals of Internal Medicine 2025 (ongoing)
- SURPASS-CVOT — Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes — NEJM 2025
- SURMOUNT-5 — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — NEJM 2025
Stable CAD
- COURAGE — Optimal Medical Therapy with or without PCI for Stable Coronary Disease — NEJM 2007
- SYNTAX — Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease — NEJM 2009
- STICH — Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction — NEJM 2011
- ORBITA — Percutaneous Coronary Intervention in Stable Angina — Lancet 2018
- ISCHEMIA — Initial Invasive or Conservative Strategy for Stable Coronary Disease — NEJM 2020
- REVIVED-BCIS 2 — Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction — NEJM 2022
- ORBITA 2 — A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina — NEJM 2023
- PREVENT — Preventive Percutaneous Coronary Intervention versus Optimal Medical Therapy Alone for the Treatment of Vulnerable Atherosclerotic Coronary Plaques — Lancet 2024
- PROMISE — Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease — JAMA Cardiology 2025
ACS
- Personal TIMI Trial Notes
- PLATO — Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes — NEJM 2009
- PLATO Criticisms — BMJ 2024
- ISAR-REACT 5 — Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes — NEJM 2019
- SENIOR-RITA — Invasive Treatment Strategy for Older Patients with Myocardial Infarction — NEJM 2024
- REBOOT-CNIC — Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction — NEJM 2025
- BETAMI-DANBLOCK — Beta-Blockers after Myocardial Infarction in Patients without Heart Failure — NEJM 2025
- TUXEDO-2 — Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease — JAMA Cardiology 2025
- AQUATIC — Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation — NEJM 2025
- PRAMI — Preventive Angioplasty in Acute Myocardial Infarction — NEJM 2013
- COMPLETE — Complete Revascularization with Multivessel PCI for Myocardial Infarction — NEJM 2019
- FULL-Revasc — FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction — NEJM 2023
- How a Meta-Analysis can Mislead—The Story of Complete vs Culprit-only PCI in STEMI — Sensible Medicine 2025
Dyslipidemia
- IMPROVE-IT — Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes — NEJM 2015
- FOURIER — Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease — NEJM 2017
- ODYSSEY — Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome — NEJM 2018
- VESALIUS-CV — Evolocumab in Patients without a Previous Myocardial Infarction or Stroke — NEJM 2025
- CORALreef — A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide — NEJM 2025
Atrial Fibrillation
Arrhythmia Management
- AFFIRM — A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation — NEJM 2002
- RACE — Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation — NEJM 2002
- RACE II — Lenient versus Strict Rate Control in Patients with Atrial Fibrillation — NEJM 2010
- EAST-AFNET 4 — Early Rhythm-Control Therapy in Patients with Atrial Fibrillation — NEJM 2020
Stroke Prophylaxis
- RE-LY — Dabigatran versus Warfarin in Patients with Atrial Fibrillation — NEJM 2009
- ARISTOTLE — Apixaban versus Warfarin in Patients with Atrial Fibrillation — NEJM 2011
- ROCKET-AF — Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation — NEJM 2011
- ENGAGE-AF — Edoxaban versus Warfarin in Patients with Atrial Fibrillation — NEJM 2013
- INVICTUS — Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation — NEJM 2022
- ARTESIA — Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation — NEJM 2023
Antithrombotic Strategy After Ablation
- OPTION — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation — NEJM 2024
- OCEAN — Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation — NEJM 2025
- ALONE-AF — Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation — JAMA 2025
Left Atrial Appendage Closure
- PROTECT-AF — Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation — Lancet 2009
- PREVAIL — Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy — JACC 2014
- PRAGUE-17 — Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation — JACC 2020
- CLOSURE-AF — Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation — NEJM 2026
- CHAMPION-AF — Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation — NEJM 2026
CHF
HFrEF
- PARADIGM-HF — Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure — NEJM 2014
- DAPA-HF — Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction — NEJM 2019
- TRED-HF — Withdrawal of Pharmacological Treatment for Heart Failure in Patients with Recovered Dilated Cardiomyopathy — Lancet 2019
- EMPEROR-REDUCED — Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure — NEJM 2020
- DIGIT-HF — Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction — NEJM 2024
- WITHDRAW-HF — Withdrawal of Heart Failure Therapy after Atrial Fibrillation Rhythm Control with Ejection Fraction Normalization — EHJ 2025
HFpEF
- Conceptual Models to Explain HFpEF: A Tale of Futility, Frustration, and Perhaps, Fruition — Circulation 2026
- TOPCAT — Spironolactone for Heart Failure with Preserved Ejection Fraction — NEJM 2014
- TOPCAT Regional Differences and Controversies — NEJM Evidence 2022
- PARAGON-HF — Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction — NEJM 2019
- EMPEROR-PRESERVED — Empagliflozin in Heart Failure with a Preserved Ejection Fraction — NEJM 2021
- DELIVER — Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction — NEJM 2022
- STEP-HFpEF — Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity — NEJM 2023
- FINEARTS-HF — Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction — NEJM 2024
- SUMMIT — Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity — NEJM 2024
- SPIRIT-HF — Spironolactone in HFmrEF and HFpEF — ACC 2026 Preliminary
Electrophysiology
- BLOCK-HF — Biventricular Pacing for Atrioventricular Block and Systolic Dysfunction — NEJM 2013
- BIOPACE — Biventricular vs. Right Ventricular Pacing Devices in Patients Anticipated to Require Frequent Ventricular Pacing — Europace 2025
- CSPACE — Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block — JACC 2025
- Physiologic Pacing in Heart Failure — NEJM 2025
- HeartSync-LBBP — Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure — JAMA Cardiology 2026
- PhysioSync-HF — Conduction System vs Biventricular Pacing in Heart Failure — JAMA Cardiology 2026
- Opposing Results From 2 Trials Comparing Conduction System Pacing and Biventricular Pacing — JAMA Cardiology 2026